Germ Cell Tumors
Epidemiology And Pathogenesis
Incidence And Demographics
- Bimodal age distribution: Peak incidence 0-4 years and puberty/adolescence (starts 9 years females, 11 years males).
- Constitute 3.5% childhood malignancies; incidence increases to 13.9% in adolescents (15-19 years).
- Annual incidence: 0.4-0.6 per 100,000 (children), peaks at 11.4 per 100,000 (adolescent males).
Risk Factors
- Klinefelter syndrome: Increased risk mediastinal germ cell tumors (GCTs).
- Testicular cancer risk factors: Cryptorchidism, trisomy 21, infertility, testicular atrophy, testicular dysgenesis syndrome.
- Orchiopexy prior to age 13 reduces testicular GCT risk.
- Highest risk observed among monozygotic twins.
Biology And Molecular Characteristics
- Originate from primordial germ cells migrating from yolk sac endoderm to gonads.
- Teilum hypothesis: Oncogenic events at different differentiation stages produce distinct histological types.
- Cytogenetics (Prepubertal vs. Postpubertal):
- Prepubertal/Children: Chromosomal gains in 1q, 11q, 20q, 22; deletions at 1p, 6q, 16q.
- Postpubertal/Adults: Isochromosome 12p amplification (present in 80% adult testicular GCTs; only 29% patients <5 years).
- Methylation patterns: Adult-type GCTs exhibit widespread hypermethylation of tumor suppressor genes (APC, RASSF1A, HIC1) causing secondary silencing of proapoptotic genes.
- MicroRNAs: Overexpression of miR-371-373 and miR-302a/302d present across all malignant GCTs. miR-371-373 upregulation correlates with cisplatin resistance.
Histological Classification
Germinomatous Tumors
- Comprise undifferentiated germ cells histologically resembling early spermatogonia or oogonia.
- Nomenclature dictated by anatomic location: Seminoma (testis), Dysgerminoma (ovary), Germinoma (extragonadal/intracranial).
Nongerminomatous Tumors (NGGCT)
| Histologic Variant | Microscopic Characteristics |
|---|---|
| Mature Teratoma | Differentiated mature tissue derived from ectoderm, mesoderm, endoderm. Mitoses absent. |
| Immature Teratoma | Immature tissue from three germinal layers. Graded 0-3 based on immaturity and neuroepithelium abundance. |
| Yolk Sac Tumor (YST) | Aggregates of undifferentiated embryonal cells. Perivascular formation with mesodermal core (Schiller-Duval body). |
| Embryonal Carcinoma (EC) | Undifferentiated cells resembling blastocyst. Polygonal cells, pink vacuolated cytoplasm, pleomorphic nucleus. |
| Choriocarcinoma (CC) | Trophoblastic differentiation. Closely packed cytotrophoblasts and multinucleate syncytiotrophoblasts. |
Clinical Manifestations
Presentation correlates with anatomic location and histologic variant.
Anatomic Distribution And Presentation
| Location | Clinical Features | Relative Frequency |
|---|---|---|
| Sacrococcygeal | Most common extragonadal site. Usually diagnosed antenatally/birth. Large mass, potential hydrops fetalis, high output cardiac failure. | 42% of extragonadal GCTs |
| Ovary | Abdominal pain, large rapidly growing mass. Precocious puberty, amenorrhea, hirsutism (with EC histology). | 24% of gonadal GCTs |
| Testis | Painless scrotal mass. Often prepubertal or postpubertal presentation. | 9% of gonadal GCTs |
| Mediastinum | Respiratory distress, anterior mediastinal mass compressing trachea/vascular structures. | 7% of extragonadal GCTs |
| Intracranial / CNS | Insidious course. Predominantly suprasellar/pineal regions. Vision changes, diabetes insipidus, pituitary deficits, precocious puberty. | 3-5% of pediatric CNS tumors |
Sacrococcygeal Teratoma Types
- Type I: Predominantly external with minimal presacral component (Most common, 8% malignant).
- Type II: External presentation with significant intrapelvic extension (21% malignant).
- Type III: Minimal external component; predominant mass extends into pelvis/abdomen (34% malignant).
- Type IV: Internalized presacral tumor without external presentation (38% malignant).
Diagnostic Evaluation
Tumor Markers
Essential for diagnosis, risk stratification, and therapeutic monitoring.
| Marker | Associated Histology | Diagnostic Utility |
|---|---|---|
| Alpha-Fetoprotein (AFP) | YST (highly elevated), EC (slight elevation). | Synthesized in embryonic liver/yolk sac. Interpret cautiously in infants (naturally elevated until 8 months). |
| Beta-hCG | Choriocarcinoma (high), Germinoma (slight), EC (slight). | Secreted by syncytiotrophoblasts. Sudden increase post-chemotherapy reflects tumor cell lysis. |
| Lactate Dehydrogenase (LDH) | Nonspecific elevation. | Nonspecific supportive marker. |
Note: Pure teratomas lack AFP/Beta-hCG production. Marker elevation associated with teratoma strongly indicates malignant germ cell elements requiring aggressive therapy.
Imaging Modalities
- Gonadal/Extragonadal: Ultrasound (testis, ovary, abdomen), cross-sectional CT (chest/abdomen/pelvis), MRI.
- Intracranial: MRI of brain and spine with Gadolinium (evaluates leptomeningeal dissemination). Lumbar puncture for CSF cytology (unless contraindicated by hydrocephalus/midline shift).
- Metastatic Surveillance: Chest CT, bone scan, PET scan. Distant metastasis present in 20% at diagnosis (lungs, liver, regional nodes, CNS, bone).
Staging And Risk Stratification
MaGIC Risk Stratification System
Malignant Germ Cell International Consortium (MaGIC) merges COG and IGCCC classifications for standardized pediatric/adolescent risk-adapted therapy.
| Risk Group | Site And Stage | Age |
|---|---|---|
| Low Risk | Testis (Stage I), Ovary (Stage I), Extragonadal (Stage I) | Any |
| Standard Risk 1 | Testis (Stage II-IV), Ovary (Stage II-IV), Extragonadal (Stage II-IV) | <11 years |
| Standard Risk 2 | Testis (IGCCC Good Risk), Ovary (Stage II-IV), Extragonadal (Stage II) | >11 years |
| Poor Risk | Testis (IGCCC Intermediate/Poor), Ovary (Stage IV), Extragonadal (Stage III-IV) | >11 years |
Management Principles
Benign Germ Cell Tumors
- Mature Teratoma: Surgical excision is curative. Examine multiple histologic sections to exclude focal immature tissue or malignant elements.
- Immature Teratoma: Surgical resection is primary therapy. Prepubertal cases unresponsive to chemotherapy. If AFP elevated, manage as malignant GCT.
- Sacrococcygeal Teratoma: Complete surgical excision including coccyx mandatory. Failure to remove coccyx results in 30-40% local recurrence rate. Incomplete resection constitutes highest risk factor for recurrence.
- Ovarian Teratoma: Fertility-sparing unilateral salpingo-oophorectomy. Contralateral ovary inspected and biopsied only if abnormal.
- Mediastinal Teratoma: Surgical excision. Neoadjuvant chemotherapy utilized for unresectable lesions abutting vital structures.
Malignant Extracranial Germ Cell Tumors
Multimodal therapy dictated by histologic subtype, anatomic site, and MaGIC risk group.
- Surgical Extirpation:
- Testicular: Radical inguinal orchiectomy with high ligation of spermatic cord. Transscrotal biopsy or capsule violation upstages disease to Stage II.
- Retroperitoneal Lymph Node Dissection (RPLND): Not indicated in prepubertal males (<6% nodal positivity). Recommended for postpubertal males with suspected clinical nodal involvement.
- Ovarian: Fertility-sparing unilateral salpingo-oophorectomy, collection of peritoneal washings, omentum inspection.
- Low Risk Therapy: Complete surgical resection followed by active surveillance (serial tumor markers and cross-sectional imaging). Safely avoids chemotherapy toxicity. Fully salvageable with platinum-based therapy upon progression.
- Standard Risk 1 (<11 years): Surgery plus 4 cycles PEb (Cisplatin, Etoposide, Bleomycin once per cycle) or JEb (Carboplatin substitution currently under prospective evaluation).
- Standard Risk 2 (>11 years): Surgery plus 3 cycles BEP (Bleomycin weekly, Etoposide, Cisplatin). Adult-equivalent bleomycin intensity required due to postpubertal biology.
- Poor Risk (>11 years): Surgery plus 4 cycles BEP.
Intracranial Germ Cell Tumors
- Pure Germinoma: Highly radiosensitive and chemosensitive. Current protocols utilize chemotherapy (Carboplatin/Etoposide) followed by reduced-dose radiation (30.6-50.4 Gy to gross tumor/ventricles depending on response). Eliminates need for craniospinal irradiation (CSI) in localized disease.
- Nongerminomatous GCT (NGGCT): Highly aggressive. Requires intensive chemotherapy (Carboplatin/Etoposide alternating with Ifosfamide/Etoposide) combined with full CSI (36 Gy) and primary site boost (54 Gy).
Relapsed And Refractory Disease
- Approximately 15-20% malignant GCTs exhibit persistent marker elevation or relapse.
- Salvage Chemotherapy Regimens: TI-CE (Paclitaxel, Ifosfamide, Carboplatin, Etoposide) or TIP (Paclitaxel, Ifosfamide, Cisplatin).
- Consolidation: High-dose chemotherapy followed by autologous peripheral blood stem cell rescue utilized for refractory/relapsed metastatic cohorts.
- Surgery: Resection of residual masses post-chemotherapy essential to differentiate persistent viable tumor from mature teratoma/fibrosis.
Prognosis And Survival
Survival correlates heavily with MaGIC risk group and anatomic location.
- Low Risk (Stage I): Outstanding outcomes. Testicular 6-year Overall Survival (OS) 100%. Ovarian 4-year OS 96% (including successful salvage cohorts).
- Standard Risk 1: 5-year OS 96-99% (Testicular), 92-97% (Ovarian), 79-91% (Extragonadal).
- Standard Risk 2: 5-year OS 83-93% (Testicular), 85% (Ovarian).
- Poor Risk: 5-year OS 83% (Testicular), 60% (Ovarian), 40% (Extragonadal).
- Intracranial Tumors: Pure germinoma OS >90%. NGGCT survival approximately 70-80% at 5 years.